Abstract
Programmed cell death, or apoptosis, is executed by a series of Cysteine Aspartyl Proteases (Caspases) that form a proteolytic cascade. Each caspase functions either to activate downstream caspases by proteolytic cleavage and / or to proteolytically cleave cellular substrates. Increased levels of apoptosis and caspase activity are frequently observed at sites of cellular damage in both acute (e.g. myocardial infarction, stroke, sepsis) and chronic (e.g. Alzheimers, Parkinsons and Huntingtons Disease) indications. Thus, inhibition of caspase activity with the aim of reducing cell death, and hence tissue damage, is predicted to be therapeutically beneficial. Herein we outline different approaches that have been taken to identify smallmolecule caspase inhibitors that include both traditional (e.g. HTS, structure-based design and substrate analog approaches) and novel screening technologies (e.g. TetheringSM). In addition, the characterization of inhibitors emerging from these programs will also be presented. Many of these compounds demonstrate efficacy in a wide range of animal models; however, only two examples of caspase inhibitors have progressed to clinical testing. Here we will discuss issues (both compound and mechanism related) associated with developing a caspase program in the pharmaceutical industry.
Keywords: apoptosis, caspases, inhibitor, extended tethering, inflammation, stroke, sepsis
Mini-Reviews in Medicinal Chemistry
Title: Prospects for Caspase Inhibitors
Volume: 4 Issue: 2
Author(s): Tom O'Brien and Dennis Lee
Affiliation:
Keywords: apoptosis, caspases, inhibitor, extended tethering, inflammation, stroke, sepsis
Abstract: Programmed cell death, or apoptosis, is executed by a series of Cysteine Aspartyl Proteases (Caspases) that form a proteolytic cascade. Each caspase functions either to activate downstream caspases by proteolytic cleavage and / or to proteolytically cleave cellular substrates. Increased levels of apoptosis and caspase activity are frequently observed at sites of cellular damage in both acute (e.g. myocardial infarction, stroke, sepsis) and chronic (e.g. Alzheimers, Parkinsons and Huntingtons Disease) indications. Thus, inhibition of caspase activity with the aim of reducing cell death, and hence tissue damage, is predicted to be therapeutically beneficial. Herein we outline different approaches that have been taken to identify smallmolecule caspase inhibitors that include both traditional (e.g. HTS, structure-based design and substrate analog approaches) and novel screening technologies (e.g. TetheringSM). In addition, the characterization of inhibitors emerging from these programs will also be presented. Many of these compounds demonstrate efficacy in a wide range of animal models; however, only two examples of caspase inhibitors have progressed to clinical testing. Here we will discuss issues (both compound and mechanism related) associated with developing a caspase program in the pharmaceutical industry.
Export Options
About this article
Cite this article as:
O'Brien Tom and Lee Dennis, Prospects for Caspase Inhibitors, Mini-Reviews in Medicinal Chemistry 2004; 4 (2) . https://dx.doi.org/10.2174/1389557043487448
DOI https://dx.doi.org/10.2174/1389557043487448 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Human Neural Stem and Progenitor Cells: In Vitro and In Vivo Properties, and Potential for Gene Therapy and Cell Replacement in the CNS
Current Gene Therapy Exercise Training-Associated Changes in Arterial Stiffness and Endothelium-Derived Vasoactive Factors
Current Hypertension Reviews Ameliorative Potential of Glycyrrhiza glabra Extracts on Memory Impairments in Stress Triggered Rats
Current Traditional Medicine Kynurenine Pathway and Disease: An Overview
CNS & Neurological Disorders - Drug Targets Innovative Formulations for the Controlled and Site-specific Delivery of Antiinflammatory Drugs
Current Pharmaceutical Design Hypoxia Inducible Factor-1 as a Target for Neurodegenerative Diseases
Current Medicinal Chemistry Metabotropic GABAB Receptors New Challenges in Drug Design
Current Medicinal Chemistry - Central Nervous System Agents Sex Hormones and their Analogues in Neuroimmune Biology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Genetic Determinants of Amyotrophic Lateral Sclerosis as Therapeutic Targets
CNS & Neurological Disorders - Drug Targets 1, 2-Benzisoxazole: A Privileged Structure with a Potential for Polypharmacology
Current Pharmaceutical Design Using Endogenous Neural Stem Cells to Enhance Recovery from Ischemic Brain Injury
Current Neurovascular Research Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Curcumin Loaded and Co-loaded Nanosystems: A Review from a Biological Activity Enhancement Perspective
Pharmaceutical Nanotechnology Astrocytic Signaling in Persistent Pain
Current Signal Transduction Therapy Nanog Overexpression Increases Neural Marker Expression in Adipose Derived Stem Cells
Recent Patents on Regenerative Medicine Tetracyclines and Pulmonary Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Serotonin 1A Receptors on Astrocytes as a Potential Target for the Treatment of Parkinson’s Disease
Current Medicinal Chemistry GABAB Receptors-Associated Proteins: Potential Drug Targets in Neurological Disorders?
Current Drug Targets Imaging of Wallerian Degeneration in the Brain
Current Medical Imaging Cellular and Molecular Mechanisms of Dementia: Decoding the Causal link of Diabetes Mellitus in Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets